Exxua access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Exxua

Exxua (gepirone) is a selective serotonin 1A (5-HT1A) receptor agonist approved by the US Food and Drug Administration for major depressive disorder in adults. The current FDA label is available at accessdata.fda.gov. Exxua is marketed by Fabre-Kramer Pharmaceuticals. Reserve Meds coordinates US-sourced cross-border access to Exxua under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the indicative drug-only cash-pay band for Exxua in each jurisdiction Reserve Meds has authored.

Exxua country-specific access guides

Reserve Meds has published 2 country-specific access guides for Exxua. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, the indicative drug-only band, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Other countries not yet authored

Reserve Meds has authored country-specific access guides for Exxua in the 2 jurisdictions listed above. If your case sits in a country that is not yet on this list, that does not mean a pathway is unavailable. It means we have not yet published the country-specific guide for Exxua. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Exxua access scope for your country

Related Reserve Meds resources


Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.